Repeated HBO Therapy in Myeloma Patients Undergoing High-Dose Therapy and Auto-HCT
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Subjects with multiple myeloma (MM) who are considered eligible for high-dose therapy and
autologous stem cell transplantation by the transplant team at WCI will be enrolled in the
study.